Cargando…
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly
Surgical resection is often not curative in patients with acromegaly and long-acting somatostatin analogues (lanreotide or octreotide) are often needed. This study assessed the efficacy and safety of self- or partner-administration of lanreotide in patients with acromegaly. This was a six-month, sin...
Autores principales: | Salvatori, Roberto, Nachtigall, Lisa B., Cook, David M., Bonert, Vivien, Molitch, Mark E., Blethen, Sandra, Chang, Stephen |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855862/ https://www.ncbi.nlm.nih.gov/pubmed/19898989 http://dx.doi.org/10.1007/s11102-009-0207-x |
Ejemplares similares
-
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry
por: Salvatori, Roberto, et al.
Publicado: (2013) -
Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective
por: Bevan, J S, et al.
Publicado: (2008) -
Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
por: Bernabéu, Ignacio, et al.
Publicado: (2020) -
Therapeutic options in the management of acromegaly: focus on lanreotide Autogel(®)
por: Roelfsema, Ferdinand, et al.
Publicado: (2008) -
Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: A case report
por: Tanaka, Sho, et al.
Publicado: (2017)